Improving Adherence to Topical Medication in Patients with Glaucoma

References

• Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390(10108):2183–2193. doi:10.1016/S0140-6736(17)31469-1
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. doi:10.1136/bjo.2005.081224
   PubMed Web of Science ®Google Scholar
• Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the melbourne visual impairment project. Ophthalmology. 1998;105(4):733–739. doi:10.1016/S0161-6420(98)94031-3
   PubMed Web of Science ®Google Scholar
• Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103(10):1661–1669. doi:10.1016/s0161-6420(96)30449-1
   PubMed Web of Science ®Google Scholar
• Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology. 1994;101(11):1851–1855. doi:10.1016/s0161-6420(94)31090-6
   Web of Science ®Google Scholar
• Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016;100(1):86–93. doi:10.1136/bjophthalmol-2015-307223
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498–505. doi:10.1016/s0002-9394(98)00272-4
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol. 2000;130(4):429–440. doi:10.1016/s0002-9394(00)00538-9
   PubMed Web of Science ®Google Scholar
• Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study G. Natural history of normal-tension glaucoma. Ophthalmology. 2001;108(2):247–253. doi:10.1016/s0161-6420(00)00518-2
   Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol. 2010;128(10):1249–1255. doi:10.1001/archophthalmol.2010.196
   PubMedGoogle Scholar
• Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030–1036. doi:10.1001/archopht.126.8.1030
   PubMedGoogle Scholar
• Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study G. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001;131(6):699–708. doi:10.1016/s0002-9394(01)00964-3
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304. doi:10.1016/S0140-6736(14)62111-5
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279. doi:10.1001/archopht.120.10.1268
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. discussion 829–30. doi:10.1001/archopht.120.6.701
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56. doi:10.1001/archopht.121.1.48
   PubMedGoogle Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943–1953. doi:10.1016/s0161-6420(01)00873-9
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111(9):1627–1635. doi:10.1016/j.ophtha.2004.02.017
   PubMed Web of Science ®Google Scholar
• Anderson DR. Normal tension glaucoma S. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14(2):86–90. doi:10.1097/00055735-200304000-00006
   PubMedGoogle Scholar
• Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging. 2015;32(7):569–581. doi:10.1007/s40266-015-0282-9
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516. doi:10.1016/S0140-6736(18)32213-X
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398–2402. doi:10.1016/j.ophtha.2011.05.013
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740. doi:10.18553/jmcp.2009.15.9.728
   PubMed Web of Science ®Google Scholar
• Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma. 1992;1(2):134–136. doi:10.1097/00061198-199201020-00012
   Google Scholar
• Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983;28:252–258. doi:10.1016/0039-6257(83)90142-x
   PubMedGoogle Scholar
• Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a Qualitative Research Study. Eye. 2009;23(4):924–932. doi:10.1038/eye.2008.103
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5):393–398. doi:10.1097/00061198-200310000-00001
   PubMed Web of Science ®Google Scholar
• Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a Qualitative Study. J Ocul Pharmacol Ther. 2002;18(5):401–409. doi:10.1089/10807680260362687
   PubMed Web of Science ®Google Scholar
• Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. doi:10.1002/14651858.CD000011.pub3
   PubMed Web of Science ®Google Scholar
• Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130(1Suppl):65S–72S. doi:10.1378/chest.130.1_suppl.65S
   Web of Science ®Google Scholar
• Deokule S, Sadiq S, Shah S. Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms. Ophthalmic Physiol Opt. 2004;24(1):9–15. doi:10.1046/j.1475-1313.2003.00155.x
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Platt R. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. Am J Manag Care. 2002;8(10 Suppl):S278–80.
   Web of Science ®Google Scholar
• DeVellis B, DeVellis R. Handbook of Health Psychology. 2001.
   Google Scholar
• Bandura A. Human agency in social cognitive theory. Paper presented at the 24th International Congress of Psychology; 1988; Sydney, Australia.
   Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123–1129 e3. doi:10.1016/j.ophtha.2007.10.031
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21(4):410–414. doi:10.5301/EJO.2010.6112
   PubMed Web of Science ®Google Scholar
• Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116(2):176–181. doi:10.1016/s0002-9394(14)71282-6
   Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598–606. doi:10.1016/j.ajo.2005.04.051
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26(3):233–236.
   PubMedGoogle Scholar
• Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–961. doi:10.1016/j.ophtha.2004.12.035
   PubMed Web of Science ®Google Scholar
• Rees G, Leong O, Crowston JG, Lamoureux EL. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology. 2010;117(5):903–908. doi:10.1016/j.ophtha.2009.10.038
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009;116(12):2286–2293. doi:10.1016/j.ophtha.2009.05.026
   PubMed Web of Science ®Google Scholar
• Ajit RR, Fenerty CH, Henson DB. Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid. Eye. 2010;24(8):1338–1343. doi:10.1038/eye.2010.27
   Web of Science ®Google Scholar
• Cate H, Broadway DC. Association between intraocular pressure and adherence: is there one? Eye. 2011;25(9):1238. doi:10.1038/eye.2011.111
   Web of Science ®Google Scholar
• Ajit RR, Fenerty CH, Henson DB. Response to cate and broadway. Eye. 2011;25(9):1238–1239. doi:10.1038/eye.2011.113
   Web of Science ®Google Scholar
• Cate H, Bhattacharya D, Clark A, Holland R, Broadway DC. A comparison of measures used to describe adherence to glaucoma medication in a randomised controlled trial. Clin Trials. 2015;12(6):608–617. doi:10.1177/1740774515592636
   Web of Science ®Google Scholar
• Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052–5057. doi:10.1167/iovs.07-0290
   PubMed Web of Science ®Google Scholar
• Hermann MM, Papaconstantinou D, Muether PS, Georgopoulos G, Diestelhorst M. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Acta Ophthalmol. 2011;89(4):e300–5. doi:10.1111/j.1755-3768.2010.02050.x
   PubMed Web of Science ®Google Scholar
• Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005;16(2):114–121. doi:10.1097/01.icu.0000156139.05323.26
   Google Scholar
• Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol. 2006;141(1 Suppl):S28–33. doi:10.1016/j.ajo.2005.09.011
   PubMed Web of Science ®Google Scholar
• Glanz K, Beck AD, Bundy L, et al. Impact of a health communication intervention to improve glaucoma treatment adherence. Results of the interactive study to increase glaucoma adherence to treatment trial. Arch Ophthalmol. 2012;130(10):1252–1258. doi:10.1001/archophthalmol.2012.1607
   PubMedGoogle Scholar
• Boland MV, Chang DS, Frazier T, Plyler R, Jefferys JL, Friedman DS. Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the Automated Dosing Reminder Study. JAMA Ophthalmol. 2014;132(7):845–850. doi:10.1001/jamaophthalmol.2014.857
   PubMed Web of Science ®Google Scholar
• Lai Y, Wu Y, Chai C, et al. The effect of patient education and telemedicine reminders on adherence to eye drops for glaucoma. Ophthalmol Glaucoma. 2020;3(5):369–376. doi:10.1016/j.ogla.2020.05.005
   PubMedGoogle Scholar
• Aguilar-Rivera M, Erudaitius DT, Wu VM, et al. Smart electronic eyedrop bottle for unobtrusive monitoring of glaucoma medication adherence. Sensors (Basel). 2020;20(9):2570. doi:10.3390/s20092570
   Web of Science ®Google Scholar
• Davies I, Williams AM, Muir KW. Aids for eye drop administration. Surv Ophthalmol. 2017;62(3):332–345. doi:10.1016/j.survophthal.2016.12.009
   Web of Science ®Google Scholar
• Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74(8):477–480. doi:10.1136/bjo.74.8.477
   PubMed Web of Science ®Google Scholar
• Rivers PH. Compliance aids–do they work? Drugs Aging. 1992;2(2):103–111. doi:10.2165/00002512-199202020-00004
   PubMed Web of Science ®Google Scholar
• Junqueira DM, Lopes FS, de Souza FC, Dorairaj S, Prata TS. Evaluation of the efficacy and safety of a new device for eye drops instillation in patients with glaucoma. Clin Ophthalmol. 2015;9:367–371. doi:10.2147/opth.S78743
   Google Scholar
• Beckers HJ, Webers CA, Busch MJ, Brink HM, Colen TP, Schouten JS. Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Acta Ophthalmol. 2013;91(7):610–618. doi:10.1111/j.1755-3768.2012.02571.x
   PubMed Web of Science ®Google Scholar
• Salyani A, Birt C. Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication. Can J Ophthalmol. 2005;40(2):170–174. doi:10.1016/s0008-4182(05)80028-6
   Web of Science ®Google Scholar
• Averns H, Hall J, Webley M. Role of opticare eye drop delivery system in patients with rheumatoid arthritis. J Rheumatol. 1999;26(12):2615–2618.
   Web of Science ®Google Scholar
• Davies IJ, Brown NH, Wen JC, et al. An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle. Clin Ophthalmol. 2016;10:1411–1417. doi:10.2147/opth.S104751
   Google Scholar
• Nordmann JP, Baudouin C, Bron A, et al. Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol. 2009;19(6):949–956. doi:10.1177/112067210901900609
   Web of Science ®Google Scholar
• Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115(8):1320–7, 1327.e1–3. doi:10.1016/j.ophtha.2007.11.023
   Web of Science ®Google Scholar
• Guven S, Koylu MT, Mumcuoglu T. Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: attitudinal perspectives among Turkish population. Eur J Ophthalmol. 2020;5. doi:10.1177/1120672120901687
   Web of Science ®Google Scholar
• Park MH, Kang KD, Moon J. Noncompliance with glaucoma medication in Korean patients: a Multicenter Qualitative Study. Jpn J Ophthalmol. 2013;57(1):47–56. doi:10.1007/s10384-012-0188-6
   Web of Science ®Google Scholar
• Rees G, Chong XL, Cheung CY, et al. Beliefs and adherence to glaucoma treatment: a comparison of patients from diverse cultures. J Glaucoma. 2014;23(5):293–298. doi:10.1097/IJG.0b013e3182741f1c
   Web of Science ®Google Scholar
• Hwang DK, Liu CJ, Pu CY, Chou YJ, Chou P. Persistence of topical glaucoma medication: a Nationwide Population-Based Cohort Study in Taiwan. JAMA Ophthalmol. 2014;132(12):1446–1452. doi:10.1001/jamaophthalmol.2014.3333
   Web of Science ®Google Scholar
• McDonald S, Ferguson E, Hagger MS, Foss AJE, King AJ. A theory-driven qualitative study exploring issues relating to adherence to topical glaucoma medications. Patient Prefer Adherence. 2019;13:819–828. doi:10.2147/ppa.S174922
   PubMed Web of Science ®Google Scholar
• Spencer SKR, Shulruf B, McPherson ZE, et al. Factors affecting adherence to topical glaucoma therapy: a Quantitative and Qualitative Pilot Study analysis in Sydney, Australia. Ophthalmol Glaucoma. 2019;2(2):86–93. doi:10.1016/j.ogla.2019.01.006
   Google Scholar
• Sheppard J, Warner J, Kelley K. An evaluation of the effectiveness of a nurse-led glaucoma monitoring clinic. Ophthalmic Nurs. 2003;7:15–21.
   Google Scholar
• Gray TA, Fenerty C, Harper R, et al. Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial. Eye. 2012;26(3):407–417. doi:10.1038/eye.2011.269
   PubMed Web of Science ®Google Scholar
• Cate H, Bhattacharya D, Clark A, Fordham R, Holland R, Broadway DC. Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). BMC Ophthalmol. 2014;14(1):32. doi:10.1186/1471-2415-14-32
   Web of Science ®Google Scholar
• Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J. 1979;2(6197):1031–1033. doi:10.1136/bmj.2.6197.1031
   PubMed Web of Science ®Google Scholar
• Waterman H, Evans JR, Gray TA, Henson D, Harper R. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2013;(4):Cd006132. doi:10.1002/14651858.CD006132.pub3
   PubMed Web of Science ®Google Scholar
• Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28(4):267–282. doi:10.2165/11588830-000000000-00000
   PubMed Web of Science ®Google Scholar
• Dogan AS, Orhan M, Soylemezoglu F, Irkec M, Bozkurt B. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol. 2004;32(1):62–66. doi:10.1046/j.1442-9071.2003.00760.x
   PubMed Web of Science ®Google Scholar
• Furrer P, Mayer JM, Plazonnet B, Gurny R. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS PharmSci. 2002;4(1):E2. doi:10.1208/ps040102
   Google Scholar
• Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12(6):486–490. doi:10.1097/00061198-200312000-00008
   PubMed Web of Science ®Google Scholar
• Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol. 2005;139(1):72–77. doi:10.1016/j.ajo.2004.08.028
   Web of Science ®Google Scholar
• Nenciu A, Stefan C, Ardelean C. [Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication]. Oftalmologia. 2004;48(1):35–42. Tratamentul topic antiglaucomatos–modificarile conjunctivale structurale si imunohitochimice. Portuguese.
   Google Scholar
• Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45(5):1360–1368. doi:10.1167/iovs.03-1067
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–423. doi:10.1136/bjo.86.4.418
   PubMed Web of Science ®Google Scholar
• Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147(4):725–735.e1. doi:10.1016/j.ajo.2008.10.019
   PubMed Web of Science ®Google Scholar
• Iester M, Oddone F, Fogagnolo P, Frezzotti P, Figus M. Changes in the morphological and functional patterns of the ocular surface in patients treated with prostaglandin analogues after the use of TSP 0.5%® preservative-free eyedrops: a Prospective, Multicenter Study. Ophthalmic Res. 2014;51(3):146–152. doi:10.1159/000357100
   Web of Science ®Google Scholar
• Asiedu K, Abu SL. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: a review. J Curr Ophthalmol. 2019;31(1):8–15. doi:10.1016/j.joco.2018.07.003
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341–349. doi:10.1177/112067210701700311
   PubMed Web of Science ®Google Scholar
• Nordmann JP, Auzanneau N, Ricard S, Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1(1):75. doi:10.1186/1477-7525-1-75
   PubMedGoogle Scholar
• Broadway DC, Tibbenham K. Tackling the NHS glaucoma clinic backlog issue. Eye. 2019;33(11):1715–1721. doi:10.1038/s41433-019-0468-1
   Web of Science ®Google Scholar
• European Glaucoma Society. European glaucoma society terminology and guidelines for glaucoma, 4th edition - chapter 3: treatment principles and options supported by the EGS foundation: part 1: foreword; introduction; glossary; chapter 3 treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195. doi:10.1136/bjophthalmol-2016-EGSguideline.003
   Web of Science ®Google Scholar
• Kaštelan S, Tomić M, Metež Soldo K, Salopek-Rabatić J. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328. doi:10.1155/2013/696328
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463. doi:10.2147/PPA.S23780
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25(2):145–152. doi:10.1089/jop.2008.0072
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. 2008;86(s242):7–13. doi:10.1111/j.1755-3768.2008.01380.x
   Web of Science ®Google Scholar
• Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26(8):1905–1913. doi:10.1185/03007995.2010.492030
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454. doi:10.2147/opth.S91402
   PubMed Web of Science ®Google Scholar
• García-Feijoo J, Muñoz-Negrete FJ, Hubatsch DA, Rossi GC. Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. Clin Ophthalmol. 2016;10:2085–2091. doi:10.2147/opth.S112711
   PubMed Web of Science ®Google Scholar
• Muñoz Negrete FJ, Lemij HG, Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol. 2017;11:557–566. doi:10.2147/opth.S126042
   PubMedGoogle Scholar
• Pillunat LE, Eschstruth P, Häsemeyer S, et al. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clin Ophthalmol. 2016;10:1759–1765. doi:10.2147/opth.S103084
   PubMed Web of Science ®Google Scholar
• Parkkari M, Latvala T, Ropo A. Handling test of eye drop dispenser–comparison of unit-dose pipettes with conventional eye drop bottles. J Ocul Pharmacol Ther. 2010;26(3):273–276. doi:10.1089/jop.2009.0111
   PubMed Web of Science ®Google Scholar
• Lazreg S, Merad Z, Nouri M, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018;41(10):945–954. doi:10.1016/j.jfo.2018.04.012
   PubMed Web of Science ®Google Scholar
• Negri L, Ferreras A, Iester M. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019;2019:4146124. doi:10.1155/2019/4146124
   PubMed Web of Science ®Google Scholar
• Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye. 2010;33(2):83–87. doi:10.1016/j.clae.2009.12.007
   PubMed Web of Science ®Google Scholar
• Doe EA, Campagna JA, Dirhs MS, Johnson AJ. Timolol 0.5% spray vs. timolol 0.5% drops for the control of intraocular pressure. Am Acad Ophthalmol. 1997;196.
   Google Scholar
• Halberg GP, Kelly SE, Morrone M. Drug delivery systems for topical ophthalmic medication. Ann Ophthalmol. 1975;7(9):1199–1204, 1207–9.
   Google Scholar
• Yang H, Leffler CT. Hybrid dendrimer hydrogel/poly(lactic-co-glycolic acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management. J Ocul Pharmacol Ther. 2013;29(2):166–172. doi:10.1089/jop.2012.0197
   Web of Science ®Google Scholar
• Shirley M. Bimatoprost implant: first approval. Drugs Aging. 2020;37(6):457–462. doi:10.1007/s40266-020-00769-8
   PubMed Web of Science ®Google Scholar
• Toffoletto N, Saramago B, Serro AP. Therapeutic ophthalmic lenses: a review. Pharmaceutics. 2021;13(1):36. doi:10.3390/pharmaceutics13010036
   Web of Science ®Google Scholar